Investigational drug · Phase 3
INCA033989
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Essential Thrombocythemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "INCA033989"
First trial start
2026
Sep 8, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INCA033989", any sponsor or status.
Conditions studied
As listed on its trial records.
- Essential Thrombocythemia
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "INCA033989" as an intervention, largest first.
- A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaPivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT07623200 · 426 participants (planned) · Start Sep 8, 2026 · Primary completion Jun 15, 2029
Drug: INCA033989; Best Available Treatment · For: Essential Thrombocythemia
Sites: Birmingham, Alabama; Gilbert, Arizona; Duarte, California · 196 sites in all
Incyte CorporationIncyte (INCY)
NCT06034002 · 290 participants (planned) · Start Dec 4, 2023 · Primary completion Oct 29, 2028
Drug: INCA033989; Ruxolitinib · For: Myeloproliferative Neoplasms
Sites: Duarte, California; Palo Alto, California; Miami, Florida · 13 sites in all
- A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT05936359 · 160 participants · Start Sep 25, 2023 · Primary completion Feb 29, 2028
Drug: INCA033989; Ruxolitinib · For: Myeloproliferative Neoplasms
Sites: Herston, Australia; Adelaide, Australia; Melbourne, Australia · 28 sites in all
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult ParticipantsActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT07448155 · 108 participants · Start Mar 19, 2026 · Primary completion Nov 14, 2026
Drug: INCA033989; Bioavailability enhancer · For: Healthy Participants
Sites: Tempe, Arizona
Newest research
PubMed records naming it or its code names, newest first.
- How could calreticulin-targeting therapies change the myelofibrosis transplant paradigm?
MacDonald A, Gannon I, Torre E, et al. · Bone Marrow Transplant 2026
- New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification.
Gangat N, Guglielmelli P, Vannucchi AM, et al. · Am J Hematol 2026
- Calreticulin and myeloproliferative neoplasms: linking biology to targeted therapies.
Lewandowski K, Loch JI · Expert Rev Clin Immunol 2026
- Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting.
Zhang T, Jiang H, Liu D · Exp Hematol Oncol 2026
- Pharmacologic management of ET: established therapies and emerging agents.
Rouf R, Tremblay D · Expert Opin Pharmacother 2025
- Challenges in the Evolving Role of Calreticulin as a Promising Target for Precision Medicine in Myeloproliferative Neoplasms.
Costa A, Breccia M · Cancers (Basel) 2025
Also in development for Essential Thrombocythemia
- BomedemstatMK-3543, IMG-7289Phase 35 trials
Merck & Co. · Polycythemia Vera, Essential Thrombocythemia, Thrombocythemia, Essential
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Incyte.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.